ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.
infoResMed is a large cap stock with a total market cap of 23.83B.
infoThey trade on the NYSE and had their IPO 28 years and 2 months ago.
infoResMed currently employs 10140 people.
infoAs of Wednesday, Aug 23 2023, ResMed’s share price is $162.0.
News Relating to ResMed
Zacks Investment Research
Here’s Why Investors Should Retain ResMed (RMD) Stock for Now
Tuesday Aug 22 2023 at 11:17
Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.
InvestorPlace
Buy the Drop: 3 Stocks to Snag After This Month’s 20% Tumble
Monday Aug 21 2023 at 16:26
August has been a great month for investors looking for bargain stocks to buy on the dip. The S&P 500, Dow Jones Industrial Average, and the Nasdaq 100 were down 2,1%, 2.0%, and 2.4%, respectively, for the week of Aug. 14-18.
InvestorPlace
5 Blue-Chip Stocks AI Thinks Will Double Your Money by 2027
Wednesday Aug 16 2023 at 12:42
In June, I introduced five stocks that AI predicted could double a portfolio in a year. Here’s how they’ve done in the first month.
The Motley Fool
2 Stocks That Could Grow Your Portfolio Over the Next Decade
Tuesday Aug 15 2023 at 09:44
ResMed offers innovative solutions for people suffering from sleep apnea and other chronic diseases. Parker-Hannifin is a leader in motion control technologies and manufactures several related products.
Forbes
Here’s Why We Think ResMed Stock Is Undervalued After An 18% Fall In A Month
Friday Aug 11 2023 at 07:00
ResMed (NYSE: RMD), a medical equipment company, has seen an 18% fall in a month, underperforming the broader S&P500 index, up 1%.
Investopedia
S&P 500 Gains and Losses Today: Stocks Lose Ground as Hiring Slows
Friday Aug 04 2023 at 17:55
The S&P 500 fell 0.5% on Friday, Aug. 4, 2023, after the Labor Department’s latest jobs report showed the pace of hiring slowed.
Zacks Investment Research
ResMed’s (RMD) Q4 Earnings Miss, Revenues Beat Estimates
Friday Aug 04 2023 at 13:32
ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.
Investopedia
Markets Higher Midday After Upbeat Earnings, July Jobs Report
Friday Aug 04 2023 at 12:50
U.S. equities were higher at midday on Friday, Aug. 4, 2023 on the back of strong earnings reports, while a cooler-than-expected July jobs report raised optimism the Fed could ease back on its campaign of rate hikes to cool inflation.
Zacks Investment Research
ResMed (RMD) Misses Q4 Earnings Estimates
Thursday Aug 03 2023 at 19:32
ResMed (RMD) came out with quarterly earnings of $1.60 per share, missing the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.49 per share a year ago.
Zacks Investment Research
Why Earnings Season Could Be Great for ResMed (RMD)
Wednesday Aug 02 2023 at 10:27
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks Investment Research
ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout
Friday Jul 07 2023 at 10:53
ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.
GlobeNewsWire
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
Thursday Jul 06 2023 at 16:05
SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on Thursday, August 3, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Seeking Alpha
Compound Your Wealth With ResMed
Tuesday Jul 04 2023 at 14:57
ResMed Inc., a leader in digital health and cloud-connected medical devices, is being considered as a potential addition to a healthcare portfolio due to its consistent financial performance and innovative product ecosystem. Despite a low yield and subdued dividend growth, the company’s focus on fundamentally-driven growth, top-tier products addressing modern health issues, and strong moat make it an appealing investment. With a healthy balance sheet, accelerating free cash flow, and a reasonable valuation, ResMed could be a potential wealth compounder for decades to come.
Zacks Investment Research
ResMed’s (RMD) New Buyout Aids Growth Amid Rising Costs
Thursday Jun 15 2023 at 11:17
ResMed’s (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.
Zacks Investment Research
Here’s Why Investors Should Retain ResMed (RMD) Stock for Now
Thursday Jun 08 2023 at 14:38
Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.
Schaeffers Research
Medical Equipment Stock to Add to Your Portfolio
Tuesday Jun 06 2023 at 14:56
Medical equipment name ResMed Inc (NYSE:RMD) is looking to snap a four-day win streak, down 0.3% at $221.33 at last glance.
GlobeNewsWire
ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
Monday Jun 05 2023 at 16:05
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, beginning at approximately 9:20 a.m. (Pacific Daylight Time) at the Waldorf Astoria Monarch Beach in Dana Point, CA.
Zacks Investment Research
ZBH vs. RMD: Which Stock Should Value Investors Buy Now?
Monday May 29 2023 at 12:50
Investors interested in stocks from the Medical – Products sector have probably already heard of Zimmer Biomet (ZBH) and ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?
Investors Business Daily
Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge
Monday May 01 2023 at 15:15
Sleep-apnea device maker ResMed broke out after earnings, continuing its accelerating growth pace. The post Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge appeared first on Investor’s Business Daily.
Zacks Investment Research
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
Friday Apr 28 2023 at 10:38
ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
Seeking Alpha
ResMed Inc. (RMD) Q3 2023 Earnings Call Transcript
Thursday Apr 27 2023 at 21:36
ResMed Inc. (RMD) Q3 2023 Earnings Call Transcript.
Seeking Alpha
ResMed Gives Investors A Good Night’s Sleep
Thursday Apr 13 2023 at 12:31
ResMed shares are selling on the expensive side of a fair value but the numbers and growth potential make us bullish on the stock. Fundamentals are strong and the forecast 6.3% annual market growth make this a stock valuable to retail value investors.
GlobeNewsWire
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
Thursday Apr 06 2023 at 16:05
SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2023 on Thursday, April 27, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
The Motley Fool
3 Incredible Growth Stocks to Buy Right Now
Wednesday Mar 22 2023 at 08:45
With the markets in flux, bargain hunters may have some prime opportunities to load up on quality names this week. Brown & Brown, Markel, and ResMed are three top-notch growth stocks worth considering in any market.
Zacks Investment Research
Reasons Why You Should Retain ResMed (RMD) Stock For Now
Thursday Mar 16 2023 at 12:14
Investors are optimistic about ResMed’s (RMD) Increased demand for its digital health solution.
Zacks Investment Research
EYE vs. RMD: Which Stock Should Value Investors Buy Now?
Tuesday Mar 07 2023 at 12:47
EYE vs. RMD: Which Stock Is the Better Value Option?
Zacks Investment Research
Reasons Why You Should Retain ResMed (RMD) Stock For Now
Wednesday Feb 15 2023 at 12:48
Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.
Zacks Investment Research
ResMed’s (RMD) Mask Sales Drive Growth, Margin Issue Lingers
Tuesday Feb 14 2023 at 11:18
ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
Seeking Alpha
ResMed: Bulls Can Rest For Now, For Its Declining Cash Flow Performance
Monday Jan 30 2023 at 15:08
ResMed continues to be a leading company in the industry, with multiple growth drivers ahead of its 2025 goals. But the outlook for ResMed doesn’t look good, with YoY figures slowing and dividend payments possibly being interrupted.
Zacks Investment Research
ESLOY vs. RMD: Which Stock Is the Better Value Option?
Friday Jan 27 2023 at 12:47
ESLOY vs. RMD: Which Stock Is the Better Value Option?
ResMed Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
ResMed’s Altman Z-score is 7.81 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
ResMed Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $1.04M of common stock in ResMed on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
ResMed’s Income Quality of 0.77 is greater than its Industry Group of 0.68 (13.2% greater)
ResMed’s Income Quality of 0.77 is in line with its Major Industry Group of 0.71 (8.5% greater)
ResMed’s Income Quality of 0.77 is in line with its Sector of 0.75 (2.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
ResMed’s Current Ratio of 3.12 is in line with its Industry Group of 3.36 (-7.1% lower)
ResMed’s Current Ratio of 3.12 is in line with its Major Industry Group of 3.13 (-0.3% lower)
ResMed’s Current Ratio of 3.12 is greater than its Sector of 2.6 (20.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (26.54 & -1.02)
Cannot compare a negative PE Ratio (26.54 & -0.58)
Cannot compare a negative PE Ratio (26.54 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
ResMed’s PB Ratio of 5.77 is greater than its Industry Group of 1.9 (203.7% greater)
ResMed’s PB Ratio of 5.77 is greater than its Major Industry Group of 1.93 (199.0% greater)
ResMed’s PB Ratio of 5.77 is greater than its Sector of 1.62 (256.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
ResMed’s ROE of 0.22 is greater than its Industry Group of -0.26 (184.6% greater)
ResMed’s ROE of 0.22 is greater than its Major Industry Group of -0.09 (344.4% greater)
ResMed’s ROE of 0.22 is greater than its Sector of -0.03 (833.3% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
ResMed’s ROCE of 0.19 is greater than its Industry Group of -0.27 (170.4% greater)
ResMed’s ROCE of 0.19 is greater than its Major Industry Group of -0.14 (235.7% greater)
ResMed’s ROCE of 0.19 is greater than its Sector of -0.04 (575.0% greater)
Derived from SEC.GOV filing dataopen_in_new